Press "Enter" to skip to content

New drug experiment against corona virus: It prevented both the development and transmission of the virus – health news

In the USA, scientists at the University of North Carolina have started to try a new drug against corona virus types.

According to the research, the effect of EIDD-2801, or Molnupiravir, on corona virus types such as SARS-CoV, MERS-CoV, SARS-CoV-2 was tested. In the experiments, the drug was found to be effective in mice transplanted with human lungs.

In addition, in the study, it was determined that the drug stopped the reproduction of Sars Cov-2 and was effective in the transmission of the virus. Research reviews published in the journal Nature stated that Molnupiravir is easier to apply compared to Remdesivir and antiviral biological drugs administered via infusion in a clinical setting.

It was also tested whether EIDD-2801 inhibits the development of SARS-CoV-2 using a dose similar to the human dose in clinical trials.


In experiments, human lung-transplanted mice were administered EIDD-2801 every 12 hours 24 hours or 48 hours after exposure to the corona virus.

According to the results, even after just two days of treatment, the drug had an effect on the replication of the virus. EIDD-2801 significantly reduced the number of infectious particles within lung tissue.

The research evaluation stated that the sooner EIDD-2801 treatment is initiated after exposure to SARS-CoV-2, the greater the reduction in virus replication will be.

Radiology Specialist Prof. Dr. Güner Sönmez shared his work on the drug on social media. Sönmez shared, “Very good news in drug treatment, we are approaching the end. Molnupiravir: Sars stops the reproduction of Cov-2. It also prevents the transmission of the virus. So it is both therapeutic and protective. This drug may be one of the turning points in the epidemic. Previously used in the treatment of flu. A drug. It is taken as a tablet. Phase 2-3 results of human experiments are expected to be released at the end of March. It seems that we will have an effective drug in 1-2 months.

Phase 2-3 trials of this drug, which has both preventive and therapeutic effects, are continuing.

Download the NTV application, stay up to date


Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *